Mae manteision cael gwared ar hepatitis B a C yn eang, i unigolion ac i'r gymdeithas ehangach. Drwy nodi a thrin pobl sydd â hepatitis B a C, gallwn sicrhau na fydd clefyd yr afu cysylltiedig â hepatitis yn datblygu, na'r cymhlethdodau sy'n deillio ohono, sy'n cael effaith sylweddol a niweidiol ar iechyd meddwl a chorfforol pobl. Yn ogystal, mae goblygiadau sylweddol o ran costau ac adnoddau i'r GIG o drin clefyd yr afu cysylltiedig â hepatitis.
The benefits of eliminating hepatitis B and C are wide ranging, both to individuals and to wider society.  By identifying and treating people with hepatitis B and C, we can prevent the development of hepatitis-related liver disease and its complications, which have a significant and detrimental impact on people’s mental and physical health. Additionally, there are significant cost and resource implications to the NHS in treating hepatitis-related liver disease.